What happened
HLB Life Science reported consolidated results for FY2025: revenue of US$32.1M (−54.5% year on year), an operating loss of US$15.2M and a net loss of US$69M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$32.1M |
|---|---|
| Revenue vs a year earlier | −54.5% |
| Operating profit | −US$15.2M |
| Net income | −US$69M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-20, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260220900848 → open original filing |
Source: DART. Information only, not investment advice.